替格瑞洛对高龄非ST段抬高型急性冠脉综合征患者疗效及安全性的回顾性分析
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Efficacy and safety of ticagrelor for the very old patients with non-ST-elevation acute coronary syndrome: a retrospective analysis of 202 cases
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    观察替格瑞洛在高龄非ST段抬高型急性冠脉综合征(NSTE-ACS)患者中的疗效与安全性。方法 连续选取海军总医院心脏中心2014年1月至2015年6月住院期间的高龄(年龄≥75岁)NSTE-ACS患者202例,根据抗血小板策略不同分为替格瑞洛组(86例)和氯吡格雷组(116例)。替格瑞洛组给予替格瑞洛180 mg负荷量后90 mg,口服,2次/d;氯吡格雷组给予氯吡格雷300 mg负荷量后75 mg,口服,1次/d,观察1年内两组患者的主要不良心脑血管事件(MACCE)发生率、严重心肌缺血复发率及出血情况。结果 替格瑞洛组发生MACCE 4例(47%),氯吡格雷组发生MACCE 16例(138%),两组患者MACCE发生率差异具有统计学意义(P=0.030)。替格瑞洛组复发严重心肌缺血4例(47%),氯吡格雷组复发严重心肌缺血8例(69%),两组患者严重心肌缺血复发率差异无统计学意义(P=0.495)。替格瑞洛组发生出血情况7例(81%),氯吡格雷组发生出血情况8例(68%),两组患者出血发生率差异无统计学意义(P=0.752)。结论 高龄NSTE-ACS行冠状动脉介入治疗患者给予替格瑞洛治疗可改善预后,且不增加出血风险。

    Abstract:

    Objective To investigate the efficacy and safety of ticagrelor in the treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in the very old patients. Methods Consecutive senior NSTE-ACS patients (≥75 years old) admitted in our hospital from January 2014 to June 2015 were enrolled in this study. According to the anti-platelet strategies, the 202 subjects were divided into ticagrelor group (n=86, initially oral loading dose of 180 mg and then continue with 90 mg twice daily) and clopidogrel group (n=116, initially oral loading dose of 300 mg and then continue with 75 mg daily). All patients were followed up for 12 months after percutaneous coronary intervention (PCI) for the incidences of major adverse cardiac and cerebral events (MACCE), recurrent myocardial ischemia and bleeding events. Results MACCE occurred in obviously fewer patients of the ticagrelor group (4 cases/4.7%) than in the clopidogrel group (16 cases/13.8%, P=0.030). Recurrent myocardial ischemia was observed in 4 cases (4.7%) from the ticagrelor group, and in 8 cases (6.9%) out of the clopidogrel group, but there was no significant difference between them (P=0.495). There were 7 cases (8.1%) of bleeding events in the ticagrelor group, and 8 cases (6.8%) in the clopidogrel group, though without significant difference between them (P=0.752). Conclusion Ticagrelor treatment can improve the prognosis and has no effect in increasing the bleeding risk in the very old NSTE-ACS patients after undergoing PCI.

    参考文献
    相似文献
    引证文献
引用本文

黄毅雄,刘如晨,郑建勇,李贤峰,曹 毅,刘英明,李田昌*.替格瑞洛对高龄非ST段抬高型急性冠脉综合征患者疗效及安全性的回顾性分析[J].中华老年多器官疾病杂志,2016,15(10):749-752
DOI:10.11915/j. issn.1671-5403.2016.10.178

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2016-06-07
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2016-10-27
  • 出版日期:
文章二维码